<DOC>
	<DOCNO>NCT01349842</DOCNO>
	<brief_summary>Evaluation use Circulating tumour Cells guide chemotherapy 3rd line chemotherapy metastatic breast cancer .</brief_summary>
	<brief_title>Circulating Tumor Cells Guide Chemotherapy Metastatic Breast Cancer</brief_title>
	<detailed_description>Phase III multicentre , randomize , open-label study compare early evaluation efficacy chemotherapy determination circulate tumour cell versus conventional clinical radiological evaluation .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Women age 18 year . WHO performance status : 0 4 . Metastatic breast cancer . Progression 2 line chemotherapy decision initiate thirdline chemotherapy . Disease evaluable CTC ( CTCpositive start chemotherapy ) . Histology : lobular ductal adenocarcinoma . Information patient signature inform consent form patient legal representative . Disease evaluable CTC ( CTCnegative start chemotherapy ) . History potentially metastatic cancer ( stage III IV cancer ) different breast cancer . Histology lobular ductal adenocarcinoma . Pregnant woman , woman likely become pregnant nursing mother . Persons deprive freedom guardianship . Women unable comply medical followup study geographical , social mental reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>